Starling Oncology, Inc., previously known as The Oncology Institute, is a prominent value-based oncology platform in the United States. The company operates a hybrid care delivery model, combining an employed physician group with a network of independent providers across more than 100 clinics and affiliated locations in states such as California, Florida, Texas, Nevada, and Oregon. Starling Oncology's business model is centered on value-based care, managing risk on oncology spending for over two million covered lives through capitated contracts and gain-share arrangements with health plans and medical groups.
The company generates revenue primarily through its in-house specialty pharmacy (dispensary), capitated contracts, and fee-for-service patient care. Recently, its specialty pharmacy segment has grown to account for over 60% of total revenue, driven by the high cost of oncology drugs and increased prescription volumes. The patient services segment, which includes capitated and fee-for-service revenue, makes up the remainder. Starling Oncology also leverages its proprietary technology platform, Starling Nexus, to streamline clinical decision support and prior authorizations. By delivering comprehensive cancer care—including clinical trials, outpatient transfusions, and care management—in a community setting, the company aims to improve patient outcomes while reducing the overall cost of oncology care.
